LGE Means Better Selection of HCM Patients for Primary Prevention Implantable Defibrillators.

[1]  R. Chan,et al.  Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. , 2016, JACC. Cardiovascular imaging.

[2]  B. Maron,et al.  Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. , 2015, The American journal of cardiology.

[3]  B. Maron,et al.  Clinical Impact of Contemporary Cardiovascular Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy , 2015, Circulation.

[4]  M. Link,et al.  Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. , 2015, Journal of the American College of Cardiology.

[5]  F. Rutten,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[6]  A. Anastasakis,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[7]  E. Cook,et al.  Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.

[8]  Barry J Maron,et al.  Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. , 2014, Journal of the American College of Cardiology.

[9]  D. Pennell,et al.  Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy , 2014, Heart.

[10]  C. Autore,et al.  Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. , 2014, The American journal of cardiology.

[11]  M. Link,et al.  Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[12]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[13]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[14]  Udo Sechtem,et al.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[15]  M. Sheppard,et al.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[16]  B. Maron.  Contemporary Reviews in Cardiovascular Medicine Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy , 2010 .

[17]  R. Rubinshtein,et al.  Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[18]  W. Manning,et al.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. , 2008, Journal of the American College of Cardiology.

[19]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.